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Abstract
Background: Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic
pancreatic cancer. This study examines the question whether GEM-based combination
chemotherapy can further improve treatment efficacy.
Methods: A meta-analysis was performed to evaluate randomized trials comparing GEM versus
GEM+X (X = cytotoxic agent). Fifteen trials including 4465 patients were eligible for an analysis of
overall survival, the primary end-point of this investigation.
Results: The meta-analysis revealed a significant survival benefit for GEM+X with a pooled hazard
ratio (HR) of 0.91 (95% CI: 0.85 – 0.97, p = 0.004). The overall test for heterogeneity resulted in
p = 0.82 (I2 = 0%). The analysis of platinum-based combinations indicated a HR of 0.85 (95% CI:
0.76 – 0.96, p = 0.010), while for fluoropyrimidine-based combinations the HR was 0.90 (95% CI:
0.81 – 0.99, p = 0.030). No risk reduction was observed in the group of trials combining GEM with
irinotecan, exatecan or pemetrexed (HR = 0.99). A meta-analysis of the trials with adequate
information on baseline performance status (PS) was performed in five trials with 1682 patients.
This analysis indicated that patients with a good PS had a marked survival benefit when receiving
combination chemotherapy (HR = 0.76; 95% CI: 0.67 – 0.87; p < 0.0001). By contrast, application
of combination chemotherapy to patients with an initially poor PS appeared to be ineffective (HR
= 1.08; 95% CI: 0.90 – 1.29, p = 0.40).
Conclusion: The meta-analysis of randomized trials indicated a significant survival benefit when
GEM was either combined with platinum analogs or fluoropyrimidines. Based on a preliminary
subgroup analysis (representing 38% of all patients included in this meta-analysis), pancreatic cancer
patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas
patients with a poor PS seem to have no survival benefit from combination chemotherapy.
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Pancreatic cancer is the fourth or fifth leading cause of
solid tumour deaths in Western industrialized countries.
Due to its predominantly late diagnosis, most patients are
diagnosed with advanced or metastatic disease at first
presentation [1,2]. Without effective treatment, a median
survival of only 3 to 4 months is expected in metastatic
disease.
Single-agent gemcitabine has evolved as a standard of care
for treatment of locally advanced and metastatic pancre-
atic cancer. However, treatment effects remain moderate
with median overall survival (OS) times in the range of 5
to 8 months and 1-year survival rates in the range of
17–25%.
To improve therapeutic efficacy numerous randomized
trials have investigated gemcitabine-based combination
regimens adding a second cytotoxic agent such as a plati-
num analog [3-7], a fluoropyrimidine [8-13], a multi-
target antifolate [14] or topoisomerase inhibitors [15-17].
While some studies showed an improvement of objective
response rates (ORR) and progression-free survival (PFS)
with combination chemotherapy, most trials lacked statis-
tical power and failed to demonstrate a statistically signif-
icant prolongation of survival. So far, only the preliminary
results of one randomized study showed a significant sur-
vival benefit in favour of combination chemotherapy
[13].
The present analysis tries to overcome the statistical limi-
tations of the individual trials and investigates the treat-
ment effects in total and in various combination groups.
Three groups characterized by the combination partner
were formed prospectively: in the first group, gemcitabine
was combined with a platinum analog like oxaliplatin or
cisplatin. The second group included fluoropyrimidines
like 5-fluorouracil (5-FU) or capecitabine as combination
partners; the third group comprised all other cytotoxic
agents such as pemetrexed, irinotecan, and exatecan.
Methods
The meta-analysis was performed according to a prospec-
tively written protocol and analysis plan.
Selection of trials
Trial selection was performed independently by three of
the authors (V. H., S. B. and A. H.); trial quality evaluation
was done by A. H. Randomized trials were selected for
evaluation when they investigated the first-line chemo-
therapy of histologically confirmed locally advanced or
metastatic pancreatic cancer. As a consequence, all studies
performed in the adjuvant or neoadjuvant setting were
excluded. Only those studies entered the analysis which
used single-agent gemcitabine in the control arm and
gemcitabine-based two-drug combination chemotherapy
in the experimental arm. The availability of adequate sur-
vival data was an inclusion criterion for the selected rand-
omized phase II and phase III studies. Since the analysis
was confined to the evaluation of chemotherapeutic
agents only, trials investigating targeted agents such as
metalloproteinase inhibitors, tipifarnib, erlotinib, bevaci-
zumab or cetuximab were not included.
Search for trials
Trials were included into the analysis which had been
published until the year 2006. The PubMed database was
searched for publications related to the use of chemother-
apy in advanced pancreatic cancer. In addition to full pub-
lications, abstracts presented at the annual meetings of the
American Society of Clinical Oncology (ASCO) and the
European Cancer Conference (ECCO) were also included.
The search was performed using the following terms:
"pancreatic cancer", "chemotherapy", "randomized con-
trolled trial". Moreover, information from medical experts
and pharmaceutical industry on additional relevant data
was retrieved.
Assessment of validity
An open assessment of the trials was performed according
to Jadad and coworkers [18].
Data abstraction
Data abstraction was performed by two independent
observers who extracted the data from the respective trials
and verified the results by comparison.
Statistical methods
Individual patient data were available in two trials only,
and were the preferred source for analysis in these cases.
The data from the other studies could be retrieved from
peer-review publications of 8 trials, while the remaining 5
trials were only recently analysed, providing the required
information in abstracts and presentation slides/posters.
Extraction of summary statistics from the published data
was performed according to standard methods for sur-
vival endpoints [19]. Standard techniques for meta-analy-
sis were used [20], as incorporated in the software
packages METASUB V. 1.1 (idv, Gauting, Germany) and
Review Manager V. 4.2 (Nordic Cochran Centre, Copen-
hagen). Both fixed (primarily) and random effect model
methodology was applied. All reported p-values result
from two-sided versions of the respective tests. The revi-
sion of funnel plots did not reveal any indications of
major publication bias.Page 2 of 11
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Characteristics of the 15 randomized trials of the meta-
analysis
This meta-analysis evaluated 4465 patients in 15 rand-
omized trials, of whom 2243 patients were included into
the control arm and 2222 patients into the combination
arm. One additional trial including 42 patients fulfilled
the selection criteria, but had to be excluded, as informa-
tion was available only as abstract and insufficient for
appropriate survival hazard analysis [21]. Single-agent
gemcitabine was generally applied in the control arms: ten
trials [3,4,6,7,9,10,12,13,15,17] used the gemcitabine reg-
imen introduced by Burris et al where gemcitabine was
given at a dose of 1000 mg/m2 (either as 30-minute infu-
sion or as fixed-dose rate (FDR) infusion with 10 mg/m2/
min) for seven out of eight weeks, then followed by a
weekly drug application for three out of four weeks [22].
In further four trials gemcitabine was given weekly times
three every four weeks [5,8,14,16], while in one trial high-
dose gemcitabine was applied at 2-week intervals [11].
Baseline characteristics of the individual trials including
gender, performance status (ECOG performance status
0–1 or Karnofsky performance status (KPS) 90–100%)
and stage of disease (locally advanced versus metastatic)
are indicated in Table 1, 2, 3. The distribution of baseline
patient characteristics within the respective 15 trials was
found to be quite homogeneous. However, between the
different trials a considerable degree of variation can be
detected. For example, the percentage of patients with
metastatic disease ranges from 54% to 100%, while the
fraction of good performance status patients varies from
24% to 88%.
Gemcitabine plus platinum analog versus single-agent 
gemcitabine
Five randomized trials compared the combination of
gemcitabine plus a platinum analog (n = 623) with gem-
citabine alone (n = 625) (Tables 1, 4, 5). They included
two oxaliplatin-based and three cisplatin-based combina-
tion studies. The platinum-based combinations induced a
significant improvement of ORR and PFS in two trials
[3,6], while the level of significance was not reached in
further three trials [4,5,7]. The platinum-based combina-
tion regimens consistently prolonged OS. None of the
individual trials showed, however, a statistically signifi-
cant superiority compared to gemcitabine alone. A signif-
icant improvement of OS was detected only when a
combined analysis of the five trials was performed (HR =
0.85, p = 0.010).
Gemcitabine plus fluoropyrimidine versus single-agent 
gemcitabine
The combination of gemcitabine with a fluoropyrimidine
was tested in six randomized trials including 1813
patients in total (912 in the control arm and 901 in the
combination arm) (Tables 2, 6, 7). Three trials used 5-FU
and further three used capecitabine as a combination part-
ner. A significant impact on ORR was observed only in the
study by Cunningham and coworkers [13], on PFS in the
trial reported by Berlin and coworkers [8]. The compara-
tive analysis of OS did not show a benefit for the combi-
nation of gemcitabine with infusional 5-FU [9,10], while
there was a trend towards an improved survival when
gemcitabine was combined with bolus 5-FU (HR = 0.82,
p = 0.09) [8].
The combined analysis of all six studies provides evidence
that a moderate, but significant prolongation of survival
can be expected from the combination of gemcitabine
with a fluoropyrimidine (HR = 0.90, p = 0.03). The com-
bination of gemcitabine with capecitabine caused a signif-
icant prolongation of OS in one trial (Cunningham),
while this was not the case in two other trials [11,12].
Nevertheless, the effect of the gemcitabine/capecitabine
combination on survival appears to show greater consist-
ency as compared to the 5-FU combinations. This is
reflected by a pooled HR of 0.83 (p = 0.01) in favour of
Table 1: Characteristics of 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog
Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Louvet 2005 156 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 70 53 82
157 Gem 1000 mg/m2/100 min d1 (FDR) + Oxaliplatin 100 mg/m2 d2 q 2 wks 68 60 83
Poplin 2006 279 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks (standard) 88 56 88
277 Gem 1500 mg/m2/150 min q wk × 3 of 4 wks (FDR) 58
276 Gem 1000 mg/m2/100 min d1 (FDR) + Oxaliplatin 100 mg/m2 d2 q 2 wks 46
Heinemann 2006 97 Gem 1000 mg/m2 for 3 of 4 wks 79 62 49*
98 Gem 1000 mg/m2 + Cisplatin 50 mg/m2 q 2 wks 80 65 56*
Colucci 2002 54 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 54 50 med. KPS 70
53 Gem 1000 mg/m2 + Cisplatin 25 mg/m2 for 6/7 wks 62 66 med. KPS 70
Viret 2004 41 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 78 na 83
42 Gem 1000 mg/m2 d1, 8, 15 + Cisplatin 75 mg/m2 d15 q 4 wks 81 na 76
* KPS = 90–100%; PS = performance status; FDR = fixed dose rate; na = data not available;Page 3 of 11
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three trials [11-13].
Gemcitabine plus other cytotoxic agent versus single-
agent gemcitabine
A total of 1404 patients were included into the remaining
four randomized trials, formally combined to the group
"other", which evaluated the combination of gemcitabine
with the multitarget antifolate pemetrexed or the topoi-
somerase inhibitors irinotecan or exatecan (Tables 3, 8,
9). Only ORR was significantly improved by the combina-
tion of gemcitabine with pemetrexed and irinotecan
[14,15]. The combined analysis of OS revealed a HR of
0.99 (p = 0.80) and failed to provide any indication for a
benefit from combination chemotherapy including these
agents.
Total analysis of 15 randomized trials
The total analysis of 15 randomized trials involving 4465
patients demonstrates a moderate, but significant benefit
from gemcitabine-based combination chemotherapy
when compared to gemcitabine alone (HR = 0.91, p =
0.004) (Table 10). Clearly this benefit is essentially
derived from combinations of gemcitabine with either
platinum analogs or fluoropyrimidines (Figure 1, fixed
effect model). Both for the total and the subgroup analy-
ses the appropriate tests do not reveal any major heteroge-
neity between the trial results. Accordingly, the
application of random effect models gave results not devi-
ating at all from those presented in the forest plot.
Subgroup analysis of performance status
A planned subgroup analysis divided patients into a good
performance status (KPS = 90–100%, ECOG 0–1) or a
poor performance status cohort (KPS 60–80%, ECOG 2).
Data from five randomized trials including 1682 patients
(1108 good performance status versus 574 poor perform-
ance status) provided evidence on treatment outcome in
the two subgroups [3,5,9,12,13]. The remaining 10 rand-
omized trials (representing 2783 patients) did not report
subgroup data based on performance status. A highly sig-
nificant benefit from combination chemotherapy was
observed in patients with a good performance status (HR
= 0.76, p < 0.001). By contrast, patients with a poor per-
formance status did not appear to benefit from combina-
tion chemotherapy (HR = 1.08, p = 0.40) (Figure 2).
Table 2: Characteristics of 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine
Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Berlin 2002 162 Gem 1000 mg/m2 for 3 of 4 wks 90 54 86
160 Gem 1000 mg/m2 + 5-FU 600 mg/m2 for 3 of 4 wks 89 52 86
Riess 2005 238 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 77 54 48*
235 Gem 1000 mg/m2 + FA 200 mg/m2 5-FU 750 mg/m2 CI × 4 wks q 6 wks 77 52 44*
DiCostanzo 2005 48 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 73 48 69
43 Gem 1000 mg/m2 + CI 5-FU 200 mg/m2 for 6 of 7 wks, then wkly for 3 of 4 
wks
67 63 67
Scheithauer 2003 42 Gem 2200 mg/m2 q 2 wks 100 55 24
41 Gem 2200 mg/m2 + Capecitabine 2500 mg/m2 d1-7 q 2 wks 100 66 27
Herrmann 2005 159 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 79 53 53*
160 Gem 1000 mg/m2 d1, 8 + Capecitabine 2 × 650 mg/m2 d1-14 q 3 wks 80 54 53*
Cunningham 2005 266 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 71 na 82
267 Gem 1000 mg/m2 d1, 8, 15 + Capecitabine 2 × 830 mg/m2 d1-21 q 4 wks 70 na 81
* KPS = 90–100%; PS = performance status; na = data not available;
Table 3: Characteristics of 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agents
Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Oettle 2005 282 Gem 1000 mg/m2 for 3 of 4 wks 92 54 88
283 Gem 1250 mg/m2 d1, 8 + Pemetrexed 500 mg/m2 d8 q 3 wks 90 60 85
Rocha Lima 2004 180 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 81 53 74
180 Gem 1000 mg/m2 + Irinotecan 100 mg/m2 d1+8 q 3 wks 82 57 78
Stathopoulos 2006 70 Gem 900 mg/m2 for 3 of 4 wks 86 60 86
60 Gem 900 mg/m2 d1, 8 + Irinotecan 300 mg/m2 d8, q 4 wks 78 65 87
O'Reilly 2004 174 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 78 57 52*
175 Gem 1000 mg/m2 d1, 8 + Exatecan 2 mg/m2 d1+8 q 3 wks 79 53 51*
* KPS = 90–100%; PS = performance status;Page 4 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:82 http://www.biomedcentral.com/1471-2407/8/82Discussion and Conclusion
Pancreatic cancer is a highly malignant disease, and sur-
vival is expected to be short in advanced disease. Once
treatment has been initiated, response evaluation by
imaging is difficult and tumor response is not regarded as
a reliable parameter of treatment efficacy. It therefore
appears that OS should be evaluated as a primary end-
point when different treatment options and therapeutic
regimens are compared. In view of the rather short course
of the disease first-line therapy is expected to have the
greatest impact on OS. Accordingly, the present meta-
analysis chose to evaluate 15 randomized trials based on
the available survival data only.
The starting point of this analysis has been the perception
that single-agent gemcitabine as the present standard of
care is only moderately active in metastatic pancreatic can-
cer and allows a median OS of only 5–8 months in rand-
omized trials. In view of the manifold trials investigating
gemcitabine-based combination therapies only two stud-
ies stand out which reported a significant improvement of
survival in favour of the combination therapy [13,23]. In
both trials patient numbers exceeded 500, and the hazard
ratios achieved in favour of the combination were nearly
identical: HR = 0.80 (p = 0.026) for gemcitabine plus
capecitabine [13], and HR = 0.81 (p = 0.025) for gemcit-
abine plus erlotinib [18].
This meta-analysis evaluated the 15 available trials com-
paring gemcitabine versus gemcitabine plus one other
chemotherapy drug excluding combined therapy with tar-
geted agents. When all 15 trials (4465 patients) are taken
together a highly significant (p = 0.004) advantage of sur-
vival is obtained in favour of combination therapy. How-
ever, the gain in survival time is slim (HR = 0.91; 95% CI
0.85 – 0.97) and clinical relevance remains moderate.
In a subsequent step, trials were grouped according to the
combination partner and separate analyses were per-
formed for combinations with either platinum analogs,
fluoropyrimidines or "other" agents (Table 10). This anal-
ysis indicated that the combination of gemcitabine plus a
Table 4: Overall response rate and PFS in 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog
Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Louvet 2005 156 Gemcitabine 17.3 0.04 3.7 0.04
157 Gemcitabine (FDR) + Oxaliplatin 26.8 5.8
Poplin 2006 279 Gemcitabine (standard) 5 -- na na
277 Gemcitabine (FDR) 10 --
276 Gemcitabine (FDR) + Oxaliplatin 9 --
Heinemann 2006 95 Gemcitabine 8.2 -- 3.1 0.053
95 Gemcitabine + Cisplatin 10.2 5.3
Colucci 2002 54 Gemcitabine 9.2 0.02 2.0 0.048
53 Gemcitabine + Cisplatin 26.4 5.0
Viret 2004 41 Gemcitabine 5 -- 2.5 ns
42 Gemcitabine + Cisplatin 7 2.2
ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; FDR = fixed dose rate; na = data not available; ns = not 
significant;
Table 5: Survival in trials comparing gemcitabine to gemcitabine plus platinum analog
Reference Year Treatment regimen Median survival (mo) p HR 95% CI
Louvet 2005 Gemcitabine 7.1 0.13 0.82 0.64 – 1.05
Gemcitabine (FDR) + Oxaliplatin 9.0
Poplin 2006 Gemcitabine (standard) 4.9 -- 0.83* 0.69 – 1.00
Gemcitabine (FDR) 6.0 -- 0.88** 0.73 – 1.05
Gemcitabine (FDR) + Oxaliplatin 5.9
Heinemann 2006 Gemcitabine 6.0 0.15 0.80 0.59 – 1.08
Gemcitabine + Cisplatin 7.5
Colucci 2002 Gemcitabine 5.0 0.48 0.87 0.58 – 1.29
Gemcitabine + Cisplatin 7.5
Viret 2004 Gemcitabine 6.7 0.73 0.92 0.59 – 1.45
Gemcitabine + Cisplatin 8.0
FDR = fixed dose rate;
* FDR Gemcitabine versus Gemcitabine
** GEMOX versus GemcitabinePage 5 of 11
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cantly superior to gemcitabine alone inducing a HR of
0.85 (p = 0.01) with a low heterogeneity of results (p =
0.97). However, one must keep in mind that the study of
Louvet and colleagues as well as the E 6201 study by Pop-
lin and co-workers used a FDR gemcitabine application
[3,4] in the combination arm (i.e., gemcitabine in the
GemOx arm was not given as a standard 30-minute infu-
sion [5-7], but at a FDR infusion of 10 mg/m2/min). Also
the combination of gemcitabine with a fluoropyrimidine
induced a significant survival benefit (HR = 0.90, p =
0.03). The somewhat heterogeneous result (p = 0.42) in
this group of trials was essentially due to the more incon-
sistent survival data obtained by the trials using 5-FU as a
combination partner. By contrast, when only the three tri-
als using capecitabine as a combination partner were ana-
lysed together, a HR of 0.83 (p = 0.01) was obtained.
This leads to the conclusion that the combination of gem-
citabine with either a platinum analog or capecitabine
may allow a clinically relevant prolongation of survival
supported by hazard ratios in the range of 0.83 – 0.85.
Compared to these positive results, combinations of gem-
citabine with either pemetrexed or topoisomerase I inhib-
itors (irinotecan or exatecan) did not have any effect on
survival (HR = 0.99) and consequently have no place in
clinical practice.
To date, five meta-analyses evaluating radiotherapy and
chemotherapy in advanced, non-resectable pancreatic
cancer have been published [24-28]. These analyses
showed that chemotherapy is able to prolong survival
(compared to best supportive care only) in patients with
advanced pancreatic cancer [24,26], and there is also evi-
dence that gemcitabine-based combination chemother-
apy may be superior to single-agent gemcitabine
regarding overall survival [25,26,28]. In accordance to our
data, the most promising survival advantage was observed
when gemcitabine was combined with either a platinum
compound or capecitabine: Sultana and colleagues in
Table 6: Overall response rate and PFS in 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine
Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Berlin 2002 162 Gemcitabine 5.6 -- 2.2
160 Gemcitabine + 5-FU (bolus) 6.9 3.4 0.022
Riess 2005 238 Gemcitabine 7.2 -- 3.5 0.44
235 Gemcitabine + 5-FU (infusional) 4.8 3.5
DiCostanzo 2005 48 Gemcitabine 8 -- 3.5 --
43 Gemcitabine + 5-FU (CI) 11 4.5
Scheithauer 2003 42 Gemcitabine 14 -- 4.0 --
41 Gemcitabine + Capecitabine 17 5.1
Herrmann 2005 159 Gemcitabine 7.9 -- 4.0 0.207
160 Gemcitabine + Capecitabine 10.1 4.8
Cunningham 2005 266 Gemcitabine 7.1 0.008 na na
267 Gemcitabine + Capecitabine 14.2 na
ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; na = data not available; CI = continuous infusion; 5-FU = 
5-fluorouracil;
Table 7: Survival in trials comparing gemcitabine to gemcitabine plus fluoropyrimidine
Reference Year Treatment regimen Median survival (mo) p HR 95% CI
Berlin 2002 Gemcitabine 5.4 0.09 0.82 0.65 – 1.03
Gemcitabine + 5-FU (bolus) 6.7
Riess 2005 Gemcitabine 6.2 0.68 1.04 0.86 – 1.25
Gemcitabine + 5-FU (infusional) 5.9
DiCostanzo 2005 Gemcitabine 7.8 -- na na
Gemcitabine + 5-FU (CI) 7.5
Scheithauer 2003 Gemcitabine 8.2 -- 0.82 0.50 – 1.35
Gemcitabine + Capecitabine 9.5
Herrmann 2005 Gemcitabine 7.3 0.314 0.89 0.70 – 1.12
Gemcitabine + Capecitabine 8.4
Cunningham 2005 Gemcitabine 6.0 0.026 0.79 0.65 – 0.97
Gemcitabine + Capecitabine 7.4
5-FU: 5-fluorouracil; CI = continuous infusion; na = data not available;Page 6 of 11
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(95% CI 0.74 – 0.96, p = 0.01) for the addition of cispla-
tin or oxaliplatin to standard gemcitabine and a HR of
0.83 (95% CI 0.72 – 0.96, p = 0.01) for the addition of
capecitabine to single-agent gemcitabine, respectively
[26]. Further meta-analytic data on treatment efficacy (e.
g. time-to-progression, progression-free survival, response
rate) and toxicity variables have also been reported
[25,27], however such an analysis was not the intent of
our investigations.
In a further step of our meta-analysis, those trials were
identified and evaluated in which survival data were
reported in patient subgroups with a defined performance
status. Data from 1682 patients only were available for
this pre-defined subgroup analysis, representing about
38% of all patients (4465) from this meta-analysis. Thus,
these results should be regarded carefully as a possible
outcome reporting bias can not be excluded. Storniolo
and coworkers had previously demonstrated that single-
agent treatment with gemcitabine induced a median sur-
vival of 5.5 months in patients with a KPS ≥ 70%, while
patients with a KPS < 70% did not appear to profit from
therapy (median OS = 2.4 months) [29]. Likewise, single
randomized studies have indicated that a benefit from
combination chemotherapy can only be expected in
patients with a good performance status [30]. The present
meta-analysis of five trials indicates that combination
chemotherapy induces its greatest benefit in patients with
a good performance status [3,5,9,12,13]. In these patients
(ECOG 0–1 or KPS = 90–100%), a combination of gem-
citabine with platinum analogs or fluoropyrimidines
induced a statistically significant and also clinically rele-
vant HR of 0.76 (p < 0.0001). By contrast, patients with a
poor KPS of 60–80% rather seem to have no survival
advantage from the more intensive combination chemo-
therapy (HR = 1.08).
In conclusion, the subgroup analysis of five large rand-
omized trials provides a possible rationale in favour of
combination chemotherapy when applied in good per-
formance status patients who can tolerate prolonged
intensive therapy. However, post-hoc subgroup analyses
from single randomized trials can only be regarded as
hypothesis-generating, and even if there is increasing evi-
dence for an important prognostic role of performance
status, a prospective evaluation of this (clinically relevant)
issue is strongly recommended for future clinical trials in
advanced pancreatic cancer. A re-evaluation of perform-
ance status data from all the 15 trials included in this
meta-analysis – even perhaps based on individual patient
data – would be another promising approach to overcome
the limitations of a possible outcome reporting bias.
This meta-analysis was focused on gemcitabine-based
chemotherapy combinations and excluded combinations
Table 8: Overall response rate and PFS in 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agent
Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Oettle 2005 282 Gemcitabine 7.1 0.004 3.3 0.111
283 Gemcitabine + Pemetrexed 14.8 3.9
Rocha Lima 2004 180 Gemcitabine 4.4 < 0.001 3.0 0.352
180 Gemcitabine + Irinotecan 16.1 3.5
Stathopoulos 2006 70 Gemcitabine 10 0.387 2.9 0.795
60 Gemcitabine + Irinotecan 15 2.8
O'Reilly 2004 174 Gemcitabine 7.1 -- 3.8 0.22
175 Gemcitabine + Exatecan 8.2 4.1
ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression;
Table 9: Survival in trials comparing gemcitabine to gemcitabine plus other cytotoxic agent
Reference Year Treatment regimen Median survival (mo) P HR 95% CI
Oettle 2005 Gemcitabine 6.3 0.848 0.98 0.82 – 1.18
Gemcitabine + Pemetrexed 6.2
Rocha Lima 2004 Gemcitabine 6.6 0.789 1.04 0.84 – 1.30
Gemcitabine + Irinotecan 6.3
Stathopoulos 2006 Gemcitabine 6.5 0.970 na na
Gemcitabine + Irinotecan 6.4
O'Reilly 2004 Gemcitabine 6.2 0.52 0.93 0.74 – 1.17
Gemcitabine + Exatecan 6.7
na = data not available;Page 7 of 11
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BMC Cancer 2008, 8:82 http://www.biomedcentral.com/1471-2407/8/82with targeted agents. The results therefore pertain only to
the referred chemotherapy doublets. Randomized trials
comparing gemcitabine versus gemcitabine plus metallo-
proteinase inhibitors, tipifarnib or bevacizumab did not
show a significant survival benefit [31-34]. More promis-
ing results were obtained from inhibition of the epider-
mal growth factor receptor (EGFR) by the oral
tyrosinekinase inhibitor erlotinib. The combination of
gemcitabine with erlotinib induced a significant improve-
ment of PFS and OS when compared to gemcitabine alone
[23]. However, preliminary data from a randomized trial
investigating the EGFR-directed antibody cetuximab as a
combination partner (SWOG S0205) did not show a sig-
nificant survival benefit for gemcitabine plus cetuximab
compared to gemcitabine monotherapy [35].
The question needs to be asked if the results of this meta-
analysis have an impact on the design of future trials per-
formed in pancreatic cancer. In conclusion, the following
statements can be made:
1. One might consider separate treatment strategies for
patients with good and poor performance status in future
clinical trials.
Meta-analysis for combination chemotherapy in advanced pancreatic cancer – overall survival with regard to combination part-ner (platinum analog, fluoropyrimidine o  other) for gemcit binFigure 1
Meta-analysis for combination chemotherapy in advanced pancreatic cancer – overall survival with regard to 
combination partner (platinum analog, fluoropyrimidine or other) for gemcitabine.
Review: GEM vs. GEM+X in advanced pancreas cancer (X = cytotoxic)
Comparison: 01 GEM vs. GEM+X                                                                                              
Outcome: 01 Overall survival                                                                                           
Study  GEM  GEM+X  Hazard Ratio (fixed)  Hazard Ratio (fixed)
or sub-category N N  log[Hazard Ratio] (SE)  95% CI  95% CI
01 Platin
01 Louvet                156        157     -0.1980 (0.1237)      0.82 [0.64, 1.05]        
02 Heinemann              95         95     -0.2230 (0.1543)      0.80 [0.59, 1.08]        
03 Colucci                54         53     -0.1450 (0.2054)      0.87 [0.58, 1.29]        
04 Viret                  41         42     -0.0800 (0.2309)      0.92 [0.59, 1.45]        
15 Poplin                279        276     -0.1278 (0.0927)      0.88 [0.73, 1.06]        
Subtotal (95% CI)      625        623        0.85 [0.76, 0.96]
Test for heterogeneity: Chi² = 0.51, df = 4 (P = 0.97), I² = 0%
Test for overall effect: Z = 2.58 (P = 0.010)
02 Fluoropyrimidine
06 Riess                 236        230      0.0380 (0.0941)      1.04 [0.86, 1.25]        
07 Berlin                162        160     -0.1990 (0.1173)      0.82 [0.65, 1.03]        
08 DiCostanzo             49         44      0.0443 (0.2262)      1.05 [0.67, 1.63]        
09 Cunningham            266        267     -0.2300 (0.1036)      0.79 [0.65, 0.97]        
10 Herrmann              157        159     -0.1200 (0.1191)      0.89 [0.70, 1.12]        
11 Scheithauer            42         41     -0.1970 (0.2518)      0.82 [0.50, 1.35]        
Subtotal (95% CI)      912        901        0.90 [0.81, 0.99]
Test for heterogeneity: Chi² = 4.98, df = 5 (P = 0.42), I² = 0%
Test for overall effect: Z = 2.16 (P = 0.03)
03 Other
12 Oettle                282        283     -0.0170 (0.0921)      0.98 [0.82, 1.18]        
13 O'Reilly              174        175     -0.0750 (0.1168)      0.93 [0.74, 1.17]        
14 Rocha Lima            180        180      0.0430 (0.1120)      1.04 [0.84, 1.30]        
16 Stathopoulos           70         60     -0.0080 (0.1969)      0.99 [0.67, 1.46]        
Subtotal (95% CI)      706        698        0.99 [0.88, 1.10]
Test for heterogeneity: Chi² = 0.53, df = 3 (P = 0.91), I² = 0%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI)     2243       2222        0.91 [0.85, 0.97]
Test for heterogeneity: Chi² = 9.10, df = 14 (P = 0.82), I² = 0%
Test for overall effect: Z = 2.88 (P = 0.004)
 0.5  0.7  1  1.5  2
 Favours GEM+X  Favours GEM  
Table 10: Meta-analysis – Survival in 15 trials comparing gemcitabine to gemcitabine + cytotoxic agent
Groups n trials n patients HR p 95% CI
Gemcitabine versus Gemcitabine + Platinum Analog 5 1248 0.85 0.010 0.76 – 0.96
Gemcitabine versus Gemcitabine + Fluoropyrimidine 6 1813 0.90 0.03 0.81 – 0.99
Gemcitabine versus Gemcitabine + other cytotoxic agent 4 1404 0.99 0.80 0.88 – 1.10
Total 15 4465 0.91 0.004 0.85 – 0.97Page 8 of 11
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BMC Cancer 2008, 8:82 http://www.biomedcentral.com/1471-2407/8/822. It has become clear that combination chemotherapy
may be a valuable tool to improve treatment efficacy in
patients with a good performance status. Further prospec-
tive exploration of intensive treatment is needed specifi-
cally in this patient group.
3. Patients with a poor performance status possibly have
no further benefit from combination chemotherapy and
thus should perhaps rather receive single-agent gemcitab-
ine. They also should be candidates for new investiga-
tional treatment approaches.
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